High-risk myeloma: OPTIMUM's extended daratumumab-based therapy held its survival lead at five years

Design

Multicentre, single-arm phase 2 trial with molecularly matched external control

Population

107 adults with newly diagnosed high-risk myeloma or plasma cell leukaemia; 120 controls

Primary outcome

Progression-free and overall survival at 5-year follow-up

Effect

PFS HR 0.32 (95% CI 0.22–0.45); OS HR 0.43 (95% CI 0.28–0.65)

OPTIMUM enrolled 107 UK patients with newly diagnosed high-risk multiple myeloma — two or more high-risk cytogenetic abnormalities, high-risk gene expression or plasma cell leukaemia — and treated them with daratumumab, cyclophosphamide, bortezomib, lenalidomide and dexamethasone induction, augmented autologous transplant, two phases of consolidation and lenalidomide-daratumumab maintenance. There was no randomised control; outcomes were compared with 120 molecularly matched patients from the earlier Myeloma XI trial.

At a median follow-up of about six years, median progression-free survival was not reached against 24.4 months in the external controls (HR 0.32, 95% CI 0.22–0.45), and median overall survival was not reached against 57.4 months (HR 0.43, 95% CI 0.28–0.65). The benefit held across high-risk subgroups except patients with three or more high-risk abnormalities.

External controls treated years earlier with different background care can exaggerate a benefit, so this is strong phase 2 evidence rather than proof. It does support routine high-risk molecular testing at diagnosis, because risk-adapted intensification depends on identifying these patients.

• Test for high-risk cytogenetic abnormalities at diagnosis so risk-adapted therapy is possible.
• Consider intensified, extended therapy for high-risk myeloma within trials or specialist protocols.
• Patients with three or more high-risk abnormalities did not share the benefit and need other approaches.
• Daratumumab-based quadruplets carry substantial cost; access in India varies widely by setting.

Why it matters

High-risk myeloma has long had the worst outcomes of the disease, and tailored intensification is the strategy now showing durable gains.

Don't overread it

The comparison is with an external, historical control group, not a randomised arm.

The statistics, in plain English

A hazard ratio of 0.43 for overall survival means the risk of death at any time was less than half that of matched controls. Because the controls come from a different, earlier trial, some of that gap may reflect improvements in general care.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.